Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Enpatoran in Active Cutaneous Lupus Erythematosus
jRCT2011250064Phase 3Not yet recruiting
- Sponsor
- Merck KGaA
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in cutaneous lupus erythematosus (CLE), discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and 2 more comparing Enpatoran 50 mg BID with Placebo BID (2 arms). Primary endpoint: CLASI-70 response at Week 24. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)acute cutaneous lupus erythematosus (ACLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2011250064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250064.